Table 5.

Patient characteristics and OS (univariate analysis)

Characteristics	No. of patients (N = 102)	Hazard ratio	95% CI	P
Age*	—	1.33†	1.07, 1.65	.010
Gender				.505
Female‡	54
Male	48	1.20	0.70, 2.05
Total number of prior systemic therapy regimens*	—	1.12	1.01, 1.24	.026
Best response achieved with most recent regimen				.537
Objective response‡	47
Stable disease	23	0.86	0.43, 1.71
Progressive disease	26	1.34	0.7, 2.58
Unknown/other	6	0.55	0.13, 2.31
Any prior cancer-related radiotherapy				.975
Yes‡	67
No	35	1.01	0.58, 1.76
Time from initial diagnosis to first dose (months)*	—	1.00	0.99, 1.00	.406
Time since diagnosis (months)/total no. of systemic therapies*	—	1.02	0.99, 1.06	.233
Time from last auto-SCT to relapse prior to b-v (months)*	—	1.00	0.98, 1.01	.694
PFS from prior cancer therapy (months)*	—	0.99	0.97, 1.01	.455
Stage at initial diagnosis,§ n (%)				.094
Stage I/II‡	51
Stage III	27	1.64	0.84, 3.19
Stage IV	20	2.04	1.04, 4.01
Baseline ECOG performance status				.004
Grade 0‡	42
Grade 1	60	2.37	1.32, 4.26
Baseline electrocardiogram				.423
Normal‡	60
Abnormal	42	1.25	0.73, 2.14
Baseline SPD per investigator (cm2)*	—	1.04||	1.00, 1.08	.033
Baseline soluble CD30 (ng/mL)*	—	1.00	1.00, 1.00	.025
Primary refractory status				.931
No‡	30
Yes	72	0.97	0.55, 1.73
Disease status relative to most recent prior therapy				.089
Refractory‡	43
Relapse	59	0.63	0.37, 1.07
Baseline B symptoms				.662
No‡	67
Yes	35	1.13	0.65, 1.97

Significant factors in the univariate analysis are indicated in italic font.

b-v, brentuximab vedotin.

^*Continuous variable.

^†Hazard ratio applies to 10-year increments.

^‡Reference level for the hazard ratio.

^§Stage was unknown for 4 patients.

^||Hazard ratio applies to 10-cm² increments.